1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Parada-Bustamante, A.; Valencia, C.; Reuquen, P.; Diaz, P.; Rincion-Rodriguez, R.; Orihuela, P.A. Role of 2-methoxy~stradiol, an
Endogenous Estrogen Metabolite, in Health and Disease. Mini. Rev. Med. Ch.em. 2015, 15, 427-438. (CrossRcf] [PubMed]
Palmisano, B.T.; Zhu, L.; Stafford, J.M. Role of Estrogens in the Regulation of Liver Lipid Metabolism. Adv. Exp. Med. Biol. 2017,
1043, 227-256. [PubMcd]
Dubey, R.K.; Jackson, E.K. Potential vascular actions of 2-methoxyestracliol. Trends Endocrinol. Metab. 2009, 20, 374-379. (CrossRcf]
[PubMcd]
Mueck, A.O.; Seeger, H. 2-Methoxyestracliol-Biology and mechanism of action. Steroids 2010, 75, 625-631. [CrossRcf]
Fielding, C.J.; Fielding, P.E. Molecular physiology of reverse cholesterol transport./. Lipid Res. 1995, 36, 211-228. [CrossRef]
Oram, J.F. Tangier disease and ABCAl. Biochim. Biuphys. Acta 2000, 1529, 321-330. [CrossRef]
Liu, W.; Qin, L.; Yu, H.; Lv, F.; Wang, Y. Apolipoprotein A-1.andadenos.ine triphosphate-binding cassett.e transporter Al expression
alleviates lipid accumulation in hepatocytes. /. Gastroenterol. Hepatol. 2014, 29, 614-622. [CrossRef]
Yang, Y.; Jiang, Y.; Wang, Y.; An, W. Suppression of ABCAl by unsaturated fatty acids leads to lipid accumulation in HepG2 cells.
Biochimie 2010, 92, 958-963. (CrossRef]
Diehl, A.M.; Day, C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N. Engl. J. Med. 2017, 377, 206~2072.
[CrossRef]
Cho, H.J.; Seo, M.J.; Lee, S.M. 2-Methoxyestracliol protects against ischemia/ reperfusion injury in alcoholic fatty liver by
enhancing sirtuin I-mediated autophagy. Biochem. Phannacol. 2017, 131, 40-51. [CrossRef]
Murao, K.; Imachi, H.; Yu, X.; Cao, W.M.; Nishiuchi, T.; Chen, K.; Li, J.; Ahmed, RA.M.; Wong, N.C.W.; Ishida, T. Interferon
alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes. Gut 2008, 57, 664-671.
[CrossRef]
Lyu, J.; Imachi, H.; Fukunaga, K.; Sato, S.; Ibata, T.; Kobayashi, T.; Dong, T.; Yoshimoto, T.; Yonezaki, K.; Nagata, H.; et al.
Angiotensin II induces cholesterol accumulation and impairs insulin secretion by regulating ABCAl in beta cells. J. Lipid Res.
2018, 59, 1906-1915. (CrossRef]
Murao, K.; Li, J.; lmachi, H.; Muraoka, T.; Masugata, H.; Zhang, G.X.; Kobayashi, R.; Ishida, T.; Tokumitsu, H. Exendin-4 regulates
glucokinase expression by CaMKK/CaMKIV pathway in pancreatic beta-cell line. Diabetes Obes. Metab. 2009, 11, 939-946.
[CrossRcf]
Yu, X.; Murao, K.; hnachi, H.; Li, J.; Nishiuchi, T.; Hosomi, N.; Masugata, H.; Zhang, G.X.; !warn.a, H.; Ishida, T. Hyperglycemia
suppress.,; ABCAl expression in vascular smooth muscle cells. Honn. Metab. Res. 2010, 42, 241-246. [CrossRe/]
Sporstol, M.; Tapia, G.; Malerod, L.; Mousavi, S.A.; Berg, T. Pregnane X receptor-agonists down-regulate hepatic ATP-binding
cassette transporter Al and scavenger receptor class B type I. .Biochem. Biuphys. Res. Commun. 2005, 331, 153~1541. [CrossRef]
Lyu, J.; Imachi, H.; Iwarna, H.; Zhang, H.; Murao, K. Insulin-like Growth Factor 1 Regulates the Expression of ATP-Binding
Cassette Transporter Al in Pancreatic Beta Cells. Honn. Metab. Res. 2016, 48, 33&-344. [CrossRef]
Nishiuchi, Y.; Murao, K.; Imachi, H.; Nishiuchi, T.; Iwama, H.; Ishida, T. Transcriptional factor prolactin regulatory elementbinding protein-mediated gene transcription of ABCAl via 31,51-cyclic adenosine-5'-monophosphate. Atherosclerosis 2010, 212,
418-425. [CrossRef]
Murao, K.; Wada, Y.; Nakamura, T.; Taylor, A.H.; Mooradian, A.O.; Wong, N.C. Effects of glucose and insulin on rat apolipoprotein
A-I gene expression. J. Biol. Chem. 1998, 273, 18959-18965. [CrossRef]
Fukunaga, K.; lmachi, H.; Lyu, J.; Dong, T.; Sato, S.; lbata, T.; Kobayashi, T.; Yoshimoto, T.; Yonezaki, K.; Matsunaga, T.; et al. IGFl
suppresses cholesterol accumulation in the liver of growth hormone-deficient mice via the activation of ABCAl. Am. J. Physiol.
Endocrinol. Metab. 2018, 315, El232-E1241. (CrossRef]
Lyu, J.; Imachi, H.; Fukunaga, K.; Sato, S.; Kobayashi, T.; Dong, T.; Saheki, T.; Matsumoto, M.; Iwama, H.; Zhang, H.; et al. Role of
ATP-binding cassette transporter Al in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes. Mo!.
Metab. 2020, 34, 16-26. [CrossRef]
Nutrients 2022, 14,288
21.
22.
23.
24.
12 of 12
Brunet, A.; Bonni, A.; Zigmond, M.J.; Lin, M.Z.; Juo, P.; fiu, L.S.; Anderson, M.J.; Arden, K.C.; Blenis, J.; Greenberg, M.E. Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96, 857-868. [CrossRef]
Liu, M.; Chung, S.; Shelness, G.S.; Parks, J.S. Hepatic ABCAl and VLDL triglyceride production. Biochim. Biophys. Acta 2012,
1821, 770-777. [CrossRef]
Koganti, S.; Snyder, R.; Gumaste, U.; i<aramyan, V.T.; Thekkumkara, T. 2-methoxyestradiol binding of GPR30 down-regulates
angiotensinAT(l) receptor. Eur. J. Pharmacol. 2014, 723, 131-140. [CrossRef]
Meyer, M.R.; Fredette, N.C.; Howard, T.A.; Hu, C.; Ramesh, C.; Daniel, C.; Amann, K.; Arterburn, J.B.; Barton, M.; Prossnitz, E.R.
G protein-coupled estrogen receptor protects from atherosclerosis. Sci. Rep. 2014, 4, 7564. [CrossRef]
25.
Wei, T.; Chen, W.; Wen, L.; Zhang, J.; Zhang, Q.; Yang, J.; Liu, H.; Chen, B.W.; Zhou, Y.; Feng, X.; et al. G protein-coupled estrogen
receptor deficiency accelerates liver tumorigenesis by enhancing inflammation and fibrosis. Cancer Lett. 2016, 382, 195-202.
[CrossRef]
26.
Vijayanathan, V.; Venkiteswaran, S.; Nair, S.K.; Verma, A.; Thomas, T.J.; Zhu, B.T.; Thomas, T. Physiologic levels of 2methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in hum.an breast cancer cells. Clin. Cancer Res.
2006, 12, 2038-2048. [CrossRef]
27.
Koganti, S.; Snyder, R,; Thekkumkara, T. Pharmacologic effects of 2-methoxyestradiol on angiotensin type 1 receptor downregulation in rat liver epithelial and aortic smooth muscle cells. Geml. Med. 2012, 9, 76-93. [CrossRef]
Verenich, S.; Gerk, P.M. Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mal. Pharm. 2010, 7,
2030-2039.[CrossRef]
Kanasaki, M.; Srivastava, S.P.; Yang, F.; Xu, L.; Kudoh, S.; Ki.tad.a, M.; Ueki, N.; Kim, H.; Li, J.; Takeda, S.; et al. Deficiency in
catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice. Sci. Rep. 2017, 7, 7927. [CrossRef]
Htun, N.C.; Miyaki, K.; Song, Y.; Ikeda, S.; Shimbo, T.; Muramatsu, M. Association of the catechol-0-methyl transferase gene
Val158Met polymorphism with blood pressure and prevalence of hypertension: Interaction with dietary energy intake. Am. J.
Hypertens 2011, 24, 1022-1026. [CrossRef] [PubMed]
Xiu, L.; Lin, M.; Liu, W.; Kong, D.; Liu, Z.; Zhang, Y.; Ouyarig, P.; Liang, Y.; Zhong, S.; Chen, C.; et al. Association ofDRD3, COMT,
and SLC6A4 Gene Polymorphisms with Type 2 Diabetes in Southern Chinese: A Hospital-Based Case-Control Study. Diabetes
Technol. Ther. 2015, 17, 580-586. [CrossRef] [PubMed]
Najib, J. Entacapone: A catechol-0-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin. Ther.
2001,23,802-832. [CrossRef]
Borges, N. Tolcapone in Parkinson's disease: Liver toxicity and clinical efficacy. Expert. Opin. Drug Saf. 2005, 4, 69-73. [CrossRef]
[PubMcd]
28.
29.
30.
31.
32.
33.
34.
35.
Martignoni, E.; Cosentino, M.; Ferrari, M.; Porta, G.; Mattarucchi, E.; Marino, F.; Lecdlini, S.; Nappi, G. Two patients with COMT
inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Neurology 2005, 65, 1820-1822. [CrossRef]
Chen, W.; Cui, Y.; Zheng, S.; Huang, J.; Li, P. Simoncini, T.; Zhang, Y.; Fu, X. 2-methoxyestradiol induces vasodilation by
stimulating NO release via PPARgamma/Pl3K/ Akt pathway. PLoS ONE 2015, 10, .0118902.
Dong, X.C. FOXO transcription factors in non-alcoholic fatty liver disease. Liver Res. 2017, 1, 168-173. [CrossRef]
Prasad, S.B.; Yadav, S.S.; Das, M.; Govardhan, H.B.; Pandey, L.K.; Singh, S.; Pradhan, S.; Narayan, G. Down Regulation of FOXOl
Promotes Cell Proliferation in Cervical Cancer. J. Cancer 2014, 5, 655-662. [CrossRef]
38. Nozhat, Z.; Mohammadi-Yeganeh, S.; Azizi, F.; Zarkesh, M.; Hedayati, M. Effects of metformin on the Pl3K/ AKT /FOXOl
pathway in anaplastic thyroid Cancer cell lines. Daru 2018, 26, 93--103. [CrossRef]
39. Kam.agate, A.; Qu, S.; Perdomo, G.; Su, D.; Kim, D.H.; Slusher, S.; Meseck, M.; Dong, H.H. FoxOl mediates insulin-dependent
regulation of hepatic VLDL production in mice. J. Clin. Investig. 2008, 118, 2347-2364. [CrossRef]
40. Cheng, Z.; White, M.F.' Targeting Forkhead box 01 from the concept to metabolic diseases: Lessons from mouse models. Antioxid.
Redox Signal. 2011, 14, 649-661. [CrossRef]
41. Valenti, L.; Rametta, R.; Dongiovanni, P.; Maggioni, M.; Fracanzani, A.L.; Zappa, M.; Lattuada, E.; Roviaro, G.; Fargion, S.
Increased expression and activity of the transcription factor FOXOl in nonalcoholic steatohepatitis. Diabetes 2008, 57, 1355-1362.
[CrossRef]
42. Banerjee, A.; Meyer, K.; Mazumdar, B.; Ray, R.B.; Ray, R. Hepatitis C virus differentially modulates activation of forkhead
transcription factors and insulin-induced metabolic gene expression. J. Viral. 2010, 84, 5936-5946. [CrossRef]
36.
37.
43.
Liu, X.;_Qiao, A.; Ke, Y.; Kong, X.; Liang, J.; Wang, R; Ouyang, X.; Zuo, J.; Chang, Y.; Fang, F. Fox01 represses LXRalpha-mediated
44.
Zhu, Y.; Liao, H.; Xie, X.; Yuan, Y.; Lee, T.; Wang, N.; Wang, X.; Shyy, J.Y.-J.; Stem.erman, M.B. Oxidized LDL downregulates
transcriptional activity of SREBP-lc promoter in HepG2 cells. FEBS Lett. 2010, 584, 4330-4334. [CrossRef]
ATP-binding cassette transporter-1 in human vascular endothelial cells via inhibiting liver X receptor (LXR). Cardiovasc. Res. 2005,
68, 425-432. [CrossRef]
45.
Lake, N.J.; Taylor, R.L.; Trahair, H.; Harikrishnan, K.N.; Curran, J.B.; Almeida, M.; Kulkarni, H.; Mukhamedova, N.; Hoang, A.;
Low, H.; et al. TRAK2, a novel regulator of ABCAl expression, cholesterol efflux and HDL biogenesis. Eur. Heart J. 2017, 38,
3579-3587. [CrossRef]
...
論文の公開元へ
